Beskrywing

The multi-drug resistance (MDR) antibiotics market in China in terms of revenue is set to grow by US$ 3 miljard tydens 2021-2027, groei teen 'n saamgestelde jaarlikse groeikoers (CAGR) van 9.7% gedurende die voorspellingsperiode, volgens die data- en ontledingsmaatskappy StrategyHelix.

Die verslag verskaf up-to-date markgrootte data vir tydperk 2017-2020 en voorspel tot 2027 covering key market aspects like sales value for multi-drug resistance (MDR) antibiotics. The China multi-drug resistance (MDR) antibiotics market is segmented on the basis of type. Volgens tipe, it is categorized into daptomycin, linezolid, teicoplanin, and tigecycline.

The report has profiled some of the key players of the market such as Chia Tai Tianqing Pharmaceutical Group Co. Bpk., Jiangsu Hansoh Pharmaceutical Group Co. Bpk., North China Pharmaceutical Company Ltd., Pfizer Inc., Zhejiang Hisun Pharmaceutical Co. Bpk., Zhejiang Medicine Co. Bpk..

Die verslag is 'n waardevolle hulpbron vir maatskappye en organisasies wat in hierdie bedryf aktief is. It provides a cohesive picture of the multi-drug resistance (MDR) antibiotics market to help drive informed decision making for industry executives, beleidmakers, akademies, en ontleders.

Verslag Omvang

Tik: daptomycin, linezolid, teicoplanin, and tigecycline
Jare oorweeg: hierdie verslag dek die tydperk 2017 aan 2027

Sleutelvoordele vir belanghebbendes

Get a comprehensive picture of the China multi-drug resistance (MDR) antibiotics market
Bepaal groeisektore en -neigings vir belegging
Understand what the future of the multi-drug resistance (MDR) antibiotics market in China looks like
Identifiseer die mededingende landskap en geleentheidsvenster

INHOUDSOPGAWE

1. Markdefinisie
2. Navorsingsmetodologie
3. Markdata & Outlook
3.1 Markwaarde
3.2 Markwaarde Voorspelling
4. Multi-Drug Resistance (MDR) Antibiotics Market by Type
4.1 Daptomycin
4.2 Linezolid
4.3 Teicoplanin
4.4 Tigecycline
5. Maatskappy profiele
5.1 Chia Tai Tianqing Pharmaceutical Group Co., Bpk.
5.2 Jiangsu Hansoh Pharmaceutical Group Co., Bpk.
5.3 North China Pharmaceutical Company Ltd.
5.4 Pfizer, Inc.
5.5 Zhejiang Hisun Pharmaceutical Co., Bpk.
5.6 Zhejiang Medicine Co., Bpk.
6. Bylaag
6.1 Oor StrategyHelix
6.2 Vrywaring